Given the abundance of AKT inhibitors in development for cancer treatment [16], we expanded our screen to include allosteric AKT inhibitors, a newer class of inhibitors that are postulated to have enhanced specificity, reduced side effects, and lower toxicity than other classes of AKT inhibitors [17]. The gene discussed is AKT1; the disease is cancer.